Liraglutide, a Glucagon-Like Peptide-1 Analog, Increased Insulin Sensitivity Assessed by Hyperinsulinemic-Euglycemic Clamp Examination in Patients with Uncontrolled Type 2 Diabetes Mellitus

Figure 1

Glucose infusion rate in euglycemic-hyperinsulinemic clamp before and after the 4-week intensive insulin-therapy and liraglutide-therapy. (a) and (b) Representative records of measurement of glucose infusion rate during euglycemic-hyperinsulinemic clamp examination before and after the 4-week liraglutide-therapy. Real trace recordings demonstrate representative results of euglycemic-hyperinsulinemic clamp in a 77-year-old male with type 2 DM. He was treated by sulfonylurea before the introduction to liraglutide-therapy. His GIR value was increased from 3.30 (a) to 7.35 (b). (c) Actual measured values of the glucose infusion rate in euglycemic-hyperinsulinemic clamp before and after the 4-week intensive insulin-therapy and liraglutide-therapy. Bar graphs represent the actual measured values of the glucose infusion rate (GIR) of the mean and standard error of mean in patients with intensive insulin-therapy () and liraglutide-therapy (). The intergroup comparisons of the posttreatment GIR values in liraglutide-therapy were significantly higher than those in intensive insulin-therapy (unpaired -test, ). The intragroup comparisons of the posttreatment GIR values were significantly higher than the pretreatment values in liraglutide-therapy (paired -test, ). Pre: pretreatment; Post: posttreatment.

(a)

(b)

(c)